Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dose-Adjusted Lymphodepletion Prior to CAR T in Renal Dysfunction
NCT05909059Phase 2Recruiting
- Sponsor
- Northside Hospital
- Start
- Nov 2024
- Primary completion
- Dec 2026
- Modality
- Orthosteric Ligands, Metabolically Activated Prodrugs
- Countries
- 1
01
Overview
Phase 2, open-label trial of fludarabine and cyclophosphamide in non-Hodgkin lymphoma (NHL), multiple myeloma (MM) and acute lymphoblastic leukemia (ALL) (3 arms), sponsored by Northside Hospital. Primary endpoints: Cytokine Release Syndrome at 90 days, Immune Effector Cell-Associated Neurotoxicity Syndrome at 90 days and 1 more. Started Nov 2024; status: recruiting.
02
Drugs
fludarabinecyclophosphamide
03
Conditions
non-Hodgkin lymphoma (NHL)multiple myeloma (MM)acute lymphoblastic leukemia (ALL)
Beyond the preview
Go deeper on NCT05909059.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05909059.